Christos Chouaid (Christos Chouaïd)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 67

Top Topics

Chronic Obstructive Pulmonary Disease

Systematic Review

Epidermal Growth Factor Receptor

Top Venues

Therapeutic advances in medical oncology

Advances in therapy

Current oncology (Toronto, Ont.)

This page only lists publications with an associated author ORCID identifier.

Publications

Jean-Bernard Auliac, Pascal-Alexandre Thomas, Olivier Bylicki, Florian Guisier, Hubert Curcio, null AlainVegnenègre, Aurelie Swalduz, Marie Wislez, Jacques Le Treut, Chantal Decroisette, Victor Basse, Lionel Falchero, Gonzague De Chabot, Diane Moreau, Eric Huchot, Audrey Lupo Mansuet, Helene Blons, Christos Chouaid, Laurent Greillier
Resected EGFR -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study). Therapeutic advances in medical oncology 16 (2024)
Simon Nannini, Florian Guisier, Hubert Curcio, Charles Ricordel, Pierre Demontrond, Safa Abdallahoui, Seyyid Baloglu, Laurent Greillier, Christos Chouaid, Roland Schott
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort. Current oncology (Toronto, Ont.) 31 (3) (2024)
Simon Nannini, Florian Guisier, Hubert Curcio, Charles Ricordel, Pierre Demontrond, Safa Abdallahoui, Seyyid Baloglu, Laurent Greillier, Christos Chouaid, Roland Schott
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort. Current oncology (Toronto, Ont.) 31 (3) (2024)
Thierry Landre, Jean-Baptiste Assié, Kader Chouahnia, Gaetan Des Guetz, Jean-Bernard Auliac, Christos Chouaid
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials. Expert review of anticancer therapy (2024)
Jean-Bernard Auliac, Pascal-Alexandre Thomas, Olivier Bylicki, Florian Guisier, Hubert Curcio, null AlainVegnenègre, Aurelie Swalduz, Marie Wislez, Jacques Le Treut, Chantal Decroisette, Victor Basse, Lionel Falchero, Gonzague De Chabot, Diane Moreau, Eric Huchot, Audrey Lupo Mansuet, Helene Blons, Christos Chouaid, Laurent Greillier
Resected EGFR -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study). Therapeutic advances in medical oncology 16 (2024)
Thierry Landre, Jean-Baptiste Assié, Kader Chouahnia, Gaetan Des Guetz, Jean-Bernard Auliac, Christos Chouaid
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials. Expert review of anticancer therapy 24 (8) (2024)
Mateo Sanchis-Borja, Florian Guisier, Aurélie Swalduz, Hubert Curcio, Victor Basse, Christophe Maritaz, Christos Chouaid, Jean-Bernard Auliac
Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France. OncoTargets and therapy 17 (2024)
Mateo Sanchis-Borja, Florian Guisier, Aurélie Swalduz, Hubert Curcio, Victor Basse, Christophe Maritaz, Christos Chouaid, Jean-Bernard Auliac
Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France. OncoTargets and therapy 17 (2024)
Thierry Landre, Jean-Baptiste Assié, Kader Chouahnia, Gaetan Des Guetz, Jean-Bernard Auliac, Christos Chouaid
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials. Expert review of anticancer therapy (2024)
Simon Nannini, Florian Guisier, Hubert Curcio, Charles Ricordel, Pierre Demontrond, Safa Abdallahoui, Seyyid Baloglu, Laurent Greillier, Christos Chouaid, Roland Schott
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort. Current oncology (Toronto, Ont.) 31 (3) (2024)
Simon Nannini, Florian Guisier, Hubert Curcio, Charles Ricordel, Pierre Demontrond, Safa Abdallahoui, Seyyid Baloglu, Laurent Greillier, Christos Chouaid, Roland Schott
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort. Current oncology (Toronto, Ont.) 31 (3) (2024)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Jean-Baptiste Assié, Christos Chouaid, Hilario Nunes, Dorothée Reynaud, Anne-Françoise Gaudin, Valentine Grumberg, Ronan Jolivel, Baptiste Jouaneton, François-Emery Cotté, Boris Duchemann
Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting. Therapeutic advances in medical oncology 15 (2023)
Jean-Baptiste Assié, Christos Chouaid, Hilario Nunes, Dorothée Reynaud, Anne-Françoise Gaudin, Valentine Grumberg, Ronan Jolivel, Baptiste Jouaneton, François-Emery Cotté, Boris Duchemann
Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting. Therapeutic advances in medical oncology 15 (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Valentine Grumberg, Christos Chouaid, Anne-Françoise Gaudin, Christophe Le Tourneau, Aurélien Marabelle, Isabelle Bongiovanni-Delarozière, François-Emery Cotté, Isabelle Borget
Organizational Impact of Immunotherapies in Advanced Cancers in France. JCO global oncology 9 (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Julia Grambow-Velilla, Romain-David Seban, Kader Chouahnia, Jean-Baptiste Assié, Laurence Champion, Nicolas Girard, Gerald Bonardel, Lise Matton, Michael Soussan, Christos Chouaid, Boris Duchemann
Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy. Cancers 15 (8) (2023)
Julia Grambow-Velilla, Romain-David Seban, Kader Chouahnia, Jean-Baptiste Assié, Laurence Champion, Nicolas Girard, Gerald Bonardel, Lise Matton, Michael Soussan, Christos Chouaid, Boris Duchemann
Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy. Cancers 15 (8) (2023)
Hélène Babey, Philippe Jamme, Hubert Curcio, Jean Baptiste Assié, Remi Veillon, Hélène Doubre, Maurice Pérol, Florian Guisier, Eric Huchot, Chantal Decroisette, Lionel Falchero, Romain Corre, Alexis Cortot, Christos Chouaid, Renaud Descourt
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study. Targeted oncology (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Renaud Descourt, Laurent Greillier, Maurice Perol, Charles Ricordel, Jean-Bernard Auliac, Lionel Falchero, Radj Gervais, Rémi Veillon, Sabine Vieillot, Florian Guisier, Marie Marcq, Grégoire Justeau, Laurence Bigay-Game, Marie Bernardi, Pierre Fournel, Hélène Doubre, Julian Pinsolle, Karim Amrane, Christos Chouaid, Chantal Decroisette
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). Cancer immunology, immunotherapy : CII (2022)
Hélène Goussault, Sébastien Gendarme, Jean-Baptiste Assié, Camille Jung, Salomé Epaud, Christelle Algans, Noémie Salaun-Penquer, Mathilde Rousseau, Andrea Lazatti, Christos Chouaid
Risk factors for early mortality of lung cancer patients in France: A nationwide analysis. Cancer medicine (2022)
Christos Chouaid, Valentine Grumberg, Alexandre Batisse, Romain Corre, Matteo Giaj Levra, Anne-Françoise Gaudin, Martin Prodel, Joannie Lortet-Tieulent, Jean-Baptiste Assié, Francois-Emery Cotté
Machine Learning-Based Analysis of Treatment Sequences Typology in Advanced Non-Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab. JCO clinical cancer informatics 6 (2022)
Valentine Grumberg, Christos Chouaid, Francois-Emery Cotté, Baptiste Jouaneton, Ronan Jolivel, Anne-Françoise Gaudin, Dorothée Reynaud, Jean-Baptiste Assié, Isabelle Borget
Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France. Journal of medical economics 25 (1) (2022)
Maxime Boussageon, Aurélie Swalduz, Christos Chouaid, Olivier Bylicki
Correction to: First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2022)
Renaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, Marie Wislez, Jacques Cadranel, Alexis Benjamin Cortot, Florian Guisier, Loïck Galland, Pascal Do, Roland Schott, Éric Dansin, Jennifer Arrondeau, Jean-Bernard Auliac, Margaux Geier, Christos Chouaid
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study. Cancers 14 (7) (2022)
Jean-Baptiste Assié, Florian Crépin, Emmanuel Grolleau, Anthony Canellas, Margaux Geier, Aude Grébert-Manuardi, Nabila Akkache, Aldo Renault, Pierre-Alexandre Hauss, Marielle Sabatini, Valentine Bonnefoy, Alexis Cortot, Marie Wislez, Clément Gauvain, Christos Chouaid, Arnaud Scherpereel, Isabelle Monnet
Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study. Cancers 14 (6) (2022)
Christos Chouaid, Michael Thomas, Didier Debieuvre, Isabelle Durand Zaleski, Stefan Zacharias, Lise Bosquet, Annika Groth, Annette Fleitz, Alan Calleja, Sonya Patel, Laure Lacoin, Melinda J Daumont, John R Penrod, Robert Carroll, Daniela Waldenberger, François-Emery Cotté, Clarisse Audigier-Valette, Frank Griesinger
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts. Cancers 14 (24) (2022)
Christos Chouaid, Michael Thomas, Didier Debieuvre, Isabelle Durand Zaleski, Stefan Zacharias, Lise Bosquet, Annika Groth, Annette Fleitz, Alan Calleja, Sonya Patel, Laure Lacoin, Melinda J Daumont, John R Penrod, Robert Carroll, Daniela Waldenberger, François-Emery Cotté, Clarisse Audigier-Valette, Frank Griesinger
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts. Cancers 14 (24) (2022)
Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier
ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date. Current oncology (Toronto, Ont.) 29 (2) (2022)
Sébastien Gendarme, Jean-Claude Pairon, Pascal Andujar, François Laurent, Patrick Brochard, Fleur Delva, Bénédicte Clin, Antoine Gislard, Christophe Paris, Isabelle Thaon, Helene Goussault, Florence Canoui-Poitrine, Christos Chouaid
Cost-Effectiveness of an Organized Lung Cancer Screening Program for Asbestos-Exposed Subjects. Cancers 14 (17) (2022)
Maxime Boussageon, Aurélie Swalduz, Christos Chouaid, Olivier Bylicki
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 36 (2) (2022)
Tina Lamy, Bastien Cabarrou, David Planchard, Xavier Quantin, Sophie Schneider, Michael Bringuier, Benjamin Besse, Nicolas Girard, Christos Chouaid, Thomas Filleron, Gaëtane Simon, Capucine Baldini
Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience. Cancers 14 (1) (2021)
Isabelle Martel-Lafay, Isabelle Monnet, Audrey Lardy-Cleaud, Serge Danhier, Naji Salem, Olivier Gallocher, Pierre Fournel, Christos Chouaid, Olivier Bylicki, null The Gfpc-Investigators
Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14). Current oncology (Toronto, Ont.) 28 (5) (2021)
Isabelle Monnet, Alain Vergnenègre, Gilles Robinet, Henri Berard, Regine Lamy, Lionel Falchero, Sabine Vieillot, Roland Schott, Charles Ricordel, Stephane Chouabe, Pascal Thomas, Radj Gervais, Anne Madroszyk, Samir Abdiche, Anne Marie Chiappa, Laurent Greillier, Chantal Decroisette, Jean-Bernard Auliac, Christos Chouaid, null null
Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis. Therapeutic advances in medical oncology 13 (2021)
Florian Scotte, Hélène Simon, Philippe Laplaige, Eric-Charles Antoine, Caroline Spasojevic, Nathalie Texier, Karine Gouhier, Christos Chouaid
Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment. BMJ supportive & palliative care (2021)
Sébastien Gendarme, Helene Goussault, Jean-Baptiste Assié, Cherifa Taleb, Christos Chouaid, Thierry Landre
Impact on All-Cause and Cardiovascular Mortality Rates of Coronary Artery Calcifications Detected during Organized, Low-Dose, Computed-Tomography Screening for Lung Cancer: Systematic Literature Review and Meta-Analysis. Cancers 13 (7) (2021)
Christos Chouaid, Thomas Filleron, Didier Debieuvre, Maurice Pérol, Nicolas Girard, Eric Dansin, Hervé Lena, Radj Gervais, Sophie Cousin, Josiane Otto, Roland Schott, David Planchard, Anne Madroszyk, Courèche Kaderbhai, Pascale Dubray-Longeras, Sandrine Hiret, Eric Pichon, Christelle Clément-Duchêne, Gaëlle Chenuc, Gaëtane Simon, Lise Bosquet, Xavier QUantin
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes. Targeted oncology 16 (6) (2021)
Helene Goussault, Sebastien Gendarme, Jean Baptiste Assié, Olivier Bylicki, Christos Chouaid
Factors associated with early lung cancer mortality: a systematic review. Expert review of anticancer therapy 21 (10) (2021)
Mireille Matrat, Murielle Gain, Corinne Haioun, Fabien Le Bras, Catherine Nisse, Franck Morschhauser, Bénédicte Clin, Isabelle Baldi, Catherine Verdun-Esquer, Robert Garnier, Hervé Laborde-Castérot, Fabrice Hérin, Yolande Esquirol, Pascal Andujar, Milia Belacel, Christos Chouaid, Claire Chauvet, Gérard Lasfargues, Jean-Claude Pairon
Development of a Questionnaire for the Search for Occupational Causes in Patients with Non-Hodgkin Lymphoma: The RHELYPRO Study. International journal of environmental research and public health 18 (8) (2021)
Valérie Gounant, Michael Duruisseaux, Ghassen Soussi, Sylvie Van Hulst, Olivier Bylicki, Jacques Cadranel, Marie Wislez, Jean Trédaniel, Jean-Philippe Spano, Carole Helissey, Christos Chouaid, Olivier Molinier, Xavier Dhalluin, Ludovic Doucet, José Hureaux, Aurélie Cazes, Gérard Zalcman
Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients. Cancers 13 (5) (2021)
Renaud Descourt, Christos Chouaid, Maurice Pérol, Benjamin Besse, Laurent Greillier, Olivier Bylicki, Charles Ricordel, Florian Guisier, Radj Gervais, Roland Schott, Jean-Bernard Auliac, Gilles Robinet, Chantal Decroisette
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50. Future oncology (London, England) 17 (23) (2021)
Nicolas Girard, Denis Moro-Sibilot, Stéphane Bouée, Corinne Emery, Elodie Torreton, Katell Le Lay, Laura Luciani, Christophe Maritaz, Christos Chouaid
Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study. Future oncology (London, England) 16 (16) (2020)
Jean-Baptiste Assié, Romain Corre, Matteo Giaj Levra, Christophe Yannick Calvet, Anne-Françoise Gaudin, Valentine Grumberg, Baptiste Jouaneton, François-Emery Cotté, Christos Chouaid
Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study). Therapeutic advances in medical oncology 12 (2020)
Romain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, Marie-Ange Massiani, Michael Soussan, Gérald Bonardel, Christos Chouaid, Margot Playe, Lucas Goldfarb, Boris Duchemann, Laura Mezquita, Nicolas Girard, Laurence Champion
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab. Cancers 12 (8) (2020)
Jean-Bernard Auliac, Sophie Bayle, Pascal Do, Gwenaëlle Le Garff, Magali Roa, Lionel Falchero, Eric Huchot, Gilles Quéré, Gaëlle Jeannin, Anne-Cécile Métivier, Joëlle Hobeika, Florian Guisier, Christos Chouaid
Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019. Cancers 12 (12) (2020)
Dominique Arpin, Marie-Christine Charpentier, Marie Bernardi, Isabelle Monnet, Aurelie Boni, Emmanuel Watkin, Isabelle Goubin-Versini, Régine Lamy, Laurence Gérinière, Margaux Geier, Fabien Forest, Radj Gervais, Anne Madrosyk, Florian Guisier, Cécile Serrand, Chrystèle Locher, Chantal Decroisette, Pierre Fournel, Jean-Bernard Auliac, Thierry Jeanfaivre, Jacques Letreut, Hélène Doubre, Geraldine Francois, Nicolas Piton, Christos Chouaid, Diane Damotte
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study. Therapeutic advances in medical oncology 12 (2020)
Alain Vergnenegre, Christos Chouaid
Economic analyses of immune-checkpoint inhibitors to treat lung cancer. Expert review of pharmacoeconomics & outcomes research 21 (3) (2020)
Margaux Geier, Renaud Descourt, Romain Corre, Guillaume Léveiller, Régine Lamy, Éric Goarant, Jean-Louis Bizec, Cyril Bernier, Gilles Quéré, Karim Amrane, Elisabeth Gaye, François Lucia, Emilie Burte, Christos Chouaid, Gilles Robinet
Duration of nivolumab for pretreated, advanced non-small-cell lung cancer. Cancer medicine 9 (19) (2020)
Quentin Gibiot, Isabelle Monnet, Pierre Levy, Anne-Laure Brun, Martine Antoine, Christos Chouaid, Jacques Cadranel, Jean-Marc Naccache
Interstitial Lung Disease Associated with Lung Cancer: A Case-Control Study. Journal of clinical medicine 9 (3) (2020)
Thierry Landre, Kader Chouahnia, Gaëtan Des Guetz, Boris Duchemann, Jean-Baptiste Assié, Christos Chouaid
First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis. Therapeutic advances in medical oncology 12 (2020)
Alain Vergnenegre, Isabelle Monnet, Acya Bizieux, Marie Bernardi, Anne Marie Chiapa, Hervé Léna, Christos Chouaid, Gilles Robinet
Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC‡ 04-2017). Future oncology (London, England) 16 (4) (2020)
Karim Amrane, Margaux Geier, Romain Corre, Hervé Léna, Guillaume Léveiller, Florence Gadby, Régine Lamy, Jean-Louis Bizec, Eric Goarant, Gilles Robinet, Sylvie Gouva, Gilles Quere, Ronan Abgral, Ulrike Schick, Cyril Bernier, Christos Chouaid, Renaud Descourt
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study. Cancer medicine 9 (7) (2020)
Jean-Bernard Auliac, Florian Guisier, Acya Bizieux, Pascal Assouline, Marie Bernardini, Régine Lamy, Grégoire Justeau, Geraldine François, Diane Damotte, Christos Chouaid
Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small-Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study). OncoTargets and therapy 13 (2020)
Jean-Bernard Auliac, Pascal Dô, Sophie Bayle, Hélène Doubre, Florent Vinas, Jacques Letreut, Lionel Falchero, Pierre Alexandre Hauss, Pascal Thomas, Christos Chouaid
Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14. Advances in therapy 36 (8) (2019)
Christos Chouaid, Mathieu Salaün, Valérie Gounant, Michel Febvre, Jean-Michel Vergnon, Vincent Jouniaux, Clément Fournier, Samy Lachkar, Christophe Hermant, Christophe Raspaud, Xavier Quantin, Jean-Jacques Quiot, Anita Molard, Charles Dayen, Charles-Hugo Marquette, Hervé Lena, Gérard Zalcman, Luc Thiberville
Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small-cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB). PloS one 14 (1) (2019)
Olivier Bylicki, Helene Barazzutti, Nicolas Paleiron, Jacques Margery, Jean-Baptiste Assié, Christos Chouaid
First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 33 (2) (2019)
Faustine Dalon, Gilles Devouassoux, Manon Belhassen, Gaëlle Nachbaur, Camille Correia Da Silva, Lynda Sail, Flore Jacoud, Christos Chouaid, Eric Van Ganse
Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy. International journal of chronic obstructive pulmonary disease 14 (2019)
Christos Chouaid, Nicola Germain, Gérard De Pouvourville, Samuel Aballéa, Daria Korchagina, Michael Baldwin, Katell Le Lay, Laura Luciani, Mondher Toumi, Philippe Devillier
Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France. Current medical research and opinion 35 (5) (2019)
Hélène Babey, Gilles Quéré, Renaud Descourt, Ronan Le Calloch, Luca Lanfranco, Jean-Baptiste Nousbaum, Divi Cornec, Alice Tison, Christos Chouaid
Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review. Expert review of anticancer therapy 18 (10) (2018)
Christos Chouaid, Jean Baptiste Assié, Pascal Andujar, Cecile Blein, Charlène Tournier, Alexandre Vainchtock, Arnaud Scherpereel, Isabelle Monnet, Jean Claude Pairon
Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis. Cancer medicine 7 (4) (2018)
Paul Lesueur, Alexandre Escande, Juliette Thariat, Enora Vauléon, Isabelle Monnet, Alexis Cortot, Delphine Lerouge, Serge Danhier, Pascal Dô, Catherine Dubos-Arvis, Christos Chouaid, Radj Gervais
Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC. Cancer medicine 7 (11) (2018)
Paul Lesueur, Isabelle Martel-Laffay, Alexandre Escande, Manon Kissel, Chrystel Locher, Radj Gervais, Roland Schott, Alain Vergnenegre, Christos Chouaid
Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review. Expert review of anticancer therapy 18 (11) (2018)
Alain Vergnenegre, Christos Chouaid
Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC). Expert review of pharmacoeconomics & outcomes research 18 (5) (2018)
Christina Pallitto, Christos Chouaid, Pim Cuijpers, William Dab, Johanna Maria van Dongen, Jaime Espin, Bengt Jönsson, Christian Léonard, David McDaid, Martin Mckee, José Pereira Miguel, Anita Patel, Jean-Yves Reginster, Walter Ricciardi, Maureen P M H Rutten-van Mölken, Valentina Prevolnik Rupel, Tracey H Sach, Franco Sassi, Norman Waugh, Roberto Bertollini
PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. International journal of technology assessment in health care 33 (6) (2017)